Investors Buy Large Volume of Omeros Call Options (NASDAQ:OMER)

Key Points

• Omeros Corporation (NASDAQ:OMER) experienced a significant increase in call options trading, with 3,697 call options purchased, representing a 422% rise compared to the typical volume.
• The company reported a quarterly loss with an EPS of ($0.65), missing expectations by ($0.05).
• Omeros has a current market cap of $220.01 million and a consensus rating of "Moderate Buy" from analysts, with an average price target of $18.00.
• Institutional investors collectively own 48.79% of Omeros's stock, highlighting strong institutional interest in the company.

Omeros Corporation (NASDAQ:OMER - Get Free Report) saw some unusual options trading on Friday. Investors purchased 3,697 call options on the stock. This is an increase of 422% compared to the average volume of 708 call options.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Omeros during the fourth quarter worth about $124,000. Wealth Enhancement Advisory Services LLC bought a new stake in Omeros during the first quarter worth approximately $579,000. Price T Rowe Associates Inc. MD boosted its holdings in Omeros by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 4,401 shares in the last quarter. GAMMA Investing LLC boosted its stake in Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 7,388 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Omeros during the 4th quarter valued at $46,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. Finally, Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. One analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Price Performance

Shares of OMER traded down $0.17 during midday trading on Tuesday, reaching $3.99. 1,175,521 shares of the stock were exchanged, compared to its average volume of 872,222. The business's 50-day moving average price is $3.38 and its 200 day moving average price is $6.24. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60. The company has a market capitalization of $233.49 million, a price-to-earnings ratio of -1.50 and a beta of 2.16.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). As a group, equities research analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.